A $35 Billion Market
Looking for a Real Answer
By 2025, over one billion women globally have reached menopause. In the United States alone, approximately 1.3 million women enter menopause every year, and the perimenopause transition — which can begin a decade earlier — affects tens of millions more. The global menopause market was valued at $21.4 billion in 2025 and is projected to reach $35.6 billion by 2032, growing at 7.5% CAGR.
Despite this scale, the majority of women navigating this transition report that existing solutions are inadequate. Hormone replacement therapy carries well-documented risks and contraindications. Over-the-counter supplements are largely underdosed and poorly absorbed. The pharmaceutical industry has historically underinvested in women's hormonal health relative to the size and severity of the need.
Perimenopause is now being called the next major frontier in women's health investment. Major media, celebrity advocacy, and a wave of femtech innovation are all converging on this space at the same moment. The demand is enormous and underserved. The timing has never been better.
Perimenopause is the new frontier. Capital is following.
In September 2025, STAT News identified perimenopause as the fastest-growing category in women's health investment. Hims and Hers launched a dedicated perimenopause treatment line in October 2025. Flo Health launched its Perimenopause Score across both major app platforms. Private equity and venture capital are entering this space in force. Sovereign ECS enters at the right moment — with a formulation, delivery mechanism, and membership model that none of these new entrants can replicate.
What Women Are Being
Offered Is Not Enough
The conventional response to perimenopause and menopause has been fragmented, inadequate, and in many cases inaccessible. Hormone replacement therapy carries significant risk profiles and is contraindicated for large portions of the target population. Low-dose OTC supplements suffer from poor bioavailability and inconsistent efficacy. The wellness industry's offerings have been largely single-symptom, single-product, and disconnected from the whole-body biology of this transition.
What women actually need is a solution that addresses the underlying regulatory system — not just the surface symptoms. One that is natural, THC-free, non-hormonal, and genuinely bioavailable. One embedded in a broader support ecosystem that recognises the emotional, spiritual, nutritional, and physiological complexity of this transition. Nothing in the current market offers all of this in a single coherent platform.
The gap is structural, not marginal. Existing CBD suppository products on the market use CBD-only or low-dose formulations that do not activate the full endocannabinoid system. Sovereign ECS deploys a 12-cannabinoid broad-spectrum formulation at 120 to 150mg per unit — delivering 4 to 6 times the therapeutic value of market alternatives. That formulation sits at the centre of a membership platform. That combination does not currently exist anywhere in the market.
The System Inside Every Woman
That Medicine Forgot
Inside every human body is a biological network that most women — and most doctors — have never been told about. It is called the endocannabinoid system, or ECS. It is one of the most widespread receptor networks in the human body, with receptors found throughout the brain, nervous system, immune tissue, reproductive organs, skin, and gut. Its primary function is homeostasis — the continuous work of keeping the body in balance.
During perimenopause and menopause, estrogen and progesterone levels fluctuate and decline — and these hormones interact directly with ECS receptor expression. As hormone levels shift, ECS function becomes dysregulated, contributing directly to the full spectrum of symptoms women experience. Supporting the ECS during this transition is not about replacing hormones. It is about restoring the body's own natural regulatory capacity.
Suppository delivery bypasses first-pass liver metabolism, delivering phytocannabinoids directly to the pelvic region where CB1 and CB2 receptors are densely expressed in the uterus, ovaries, and surrounding tissue. Bioavailability of 70 to 90% versus 6 to 20% for oral CBD products.
The 12-cannabinoid Sovereign ECS formulation — CBD, CBDA, CBG, CBGA, CBN, CBL, and additional minor cannabinoids — activates both CB1 and CB2 receptors simultaneously. Single-compound CBD isolate products activate neither receptor directly. The difference in therapeutic scope is categorical, not incremental.
THC-free, non-psychoactive, and entirely free of synthetic hormones. Broad-spectrum hemp-derived phytocannabinoids only. Safe for women who cannot or choose not to use HRT, and for those who want a natural whole-body approach that works with their biology.
A Formulation Built for
Precision and Purpose
Sovereign ECS suppositories are the centrepiece of the offering — a precision-formulated, broad-spectrum phytocannabinoid product available in two targeted SKUs. Four years of research and development, including an active pilot study with real participants, underpin the formulation design.
| SKU | Total Potency | mg / Unit | Supply | MSRP | Target |
|---|---|---|---|---|---|
| Menstrual Support PMS | 2,250 mg | 150 mg | 15-day | $109 | Women 18–45, cyclical symptoms |
| Menopause / Perimenopause | 1,800 mg | 120 mg | 30-day | $99 | Women 40–60, hormonal transition |
More Than a Product.
A Complete Ecosystem.
The suppository is the anchor. The membership is the moat. Sovereign ECS is designed not as a product business but as a women's wellness platform — a subscription membership that delivers the ECS formulation alongside a curated ecosystem of holistic support tailored to each member's stage of hormonal transition. This model dramatically increases customer lifetime value, reduces churn, and creates a category of loyalty that product-only businesses cannot approach.
Members receive physical subscription boxes delivered directly to their homes each month, and access the Sovereign ECS digital member platform — combining product delivery with exclusive educational content, practitioner guidance, and curated wellness resources across six integrated pillars.
Subscription membership fundamentally changes the unit economics.
A one-time product purchase has a single revenue event. A membership subscriber generates recurring monthly revenue across an average relationship that, for women's wellness platforms, extends 18 to 36 months or more. A base membership at $89 per month across a cohort of 500 subscribers generates $534,000 in annual recurring revenue before any product upsell, premium tier upgrade, or affiliate income is counted. The membership model also creates data depth that enables genuine personalisation and a defensible platform position that pure-product competitors cannot replicate.
Why Sovereign ECS
Cannot Be Easily Replicated
The women's hormonal wellness market is growing rapidly but remains dominated by single-symptom products, low-potency CBD offerings, and generic subscription boxes with no clinical anchor. Sovereign ECS occupies a position no current competitor holds — a precision-formulated, scientifically grounded ECS activation product embedded within a holistic membership platform.
| Brand / Product | mg / Unit | Cannabinoid Profile | MSRP | $/mg | Membership |
|---|---|---|---|---|---|
| Sovereign ECS — Menstrual Us | 150 mg | 12 cannabinoids, broad-spectrum | $109 | $0.05 | Full platform |
| Sovereign ECS — Menopause Us | 120 mg | 12 cannabinoids, broad-spectrum | $99 | $0.06 | Full platform |
| Foria Relief Melts | 100 mg | CBD only | $48 | $0.06 | None |
| Hello Again | ~25 mg | Full-spectrum with THC | $55 | $0.28 | None |
| Healing Rose | 100 mg | CBG and CBD only | $150 | $0.05 | None |
No competitor combines clinical-grade cannabinoid potency with a holistic membership platform. Sovereign ECS is 4 to 6 times better value per mg than Hello Again and significantly broader in cannabinoid profile than all current alternatives.
The Pilot Study —
Results Being Collected Now
Sovereign ECS is not a concept. The formulation is made. Product has been delivered to a real pilot study cohort of women, currently working through a structured programme with baseline and follow-up questionnaires capturing changes across eight key symptom categories.
Participants complete a structured protocol using 15 Sovereign ECS suppositories administered every other day, with questionnaires at baseline, week 1, week 2, week 3, and week 4 post-completion. The study is measuring changes across sleep quality, mood and emotional resilience, hot flushes and temperature regulation, joint comfort and physical ease, energy and vitality, cognitive clarity, libido and vaginal comfort, and overall wellbeing.
Seven women are enrolled across the perimenopausal, menopausal, and pre-menopausal stages, aged 35 to 54. All signed informed consent. Six questionnaire responses have been collected across weeks one and two of the protocol, with further check-ins ongoing through week four post-completion.
Six Responses In.
The Signal Is Already Clear.
With six questionnaire responses collected across weeks one and two of the pilot, early patterns are emerging across all twelve symptom categories. Scores are reported on a 1 to 10 scale where higher scores indicate improvement relative to baseline. All six respondents reported noticing change in a positive direction. Four of six expressed confidence the product is working for them. Five of six used the suppositories consistently throughout the period.
| Symptom Category | Avg Score / 10 | Responses | Signal |
|---|---|---|---|
| Stress Management | 6.5 / 10 | 6 | Strongest early signal |
| Mood Stability | 6.3 / 10 | 6 | Consistent across cohort |
| Overall Quality of Life | 6.3 / 10 | 6 | Consistent across cohort |
| Emotional Resilience | 6.3 / 10 | 6 | Consistent across cohort |
| Energy Levels | 6.0 / 10 | 6 | Emerging |
| Joint Comfort | 5.8 / 10 | 6 | Emerging |
| Night Sweats / Temperature | 5.7 / 10 | 6 | Emerging |
| Libido | 5.7 / 10 | 6 | Emerging |
| Cognitive Clarity | 5.5 / 10 | 6 | Early stage |
| Sleep Quality | 5.3 / 10 | 6 | Early stage |
| Hot Flush Frequency | 5.3 / 10 | 6 | Early stage |
| Vaginal Comfort | 5.2 / 10 | 6 | Early stage |
All scores are self-reported improvement ratings on a 1–10 scale relative to individual baseline. Data collected at weeks 1 and 2 only — the full protocol runs through week 4 post-completion. Scores in the 5–6 range at this stage are consistent with or above comparable early-phase outcomes for natural ECS support products. Categories rated 6.3+ represent the strongest early signals.
The qualitative signal reinforces the numbers.
"I feel brighter — if that is a response."
"I have been under a tremendous amount of extra stress and feel like the products have helped me stay functional. Some sleep improvement is noted."
"Overall much better than typical pre-menstrual symptoms."
"I feel like I handled my stressors better than I would have without it."
Context for investors: These are early-stage week 1 and week 2 scores. ECS support compounds accumulate systemic effect over time — weeks 3 and 4, and the post-completion follow-up questionnaires, are where the most significant outcome data is expected to emerge. The early signal in stress management, mood, and emotional resilience is consistent with what the science of ECS modulation would predict as the first areas of measurable response. Full results will be shared with investors as the cohort completes the protocol.
Two Raises. Two Stages.
A Clear Path to Scale.
Sovereign ECS is structured around a two-stage capital approach. The first raise is purely operational — getting the business live, the product manufactured, and the first members subscribed using existing in-house lab capacity. The second raise is a social media and organic growth engine that drives meaningful customer acquisition at scale. Both are intentionally modest relative to the returns they are designed to unlock.
$10,000 – $30,000 to get Sovereign ECS live
This raise covers the essentials to move from pilot to commercial operation. At $10,000 the business launches in lean bootstrap mode using existing in-house lab capacity producing up to 60 packs per day. At $30,000 the launch is fuller — more initial inventory, a complete website and membership platform, and professional packaging ready for first subscribers. No co-packer is required at this stage. The business is cash-generative from the first sales at a 71–73% gross margin.
| Use of Operational Funds | $10k Scenario | $20k Scenario | $30k Scenario |
|---|---|---|---|
| Ingredients and initial batch production | $4,500 | $8,000 | $12,000 |
| Packaging, seals, boxes, labels | $2,000 | $3,500 | $5,000 |
| Website and membership platform | $1,500 | $4,000 | $6,500 |
| Legal, compliance, and IP basics | $1,000 | $2,500 | $4,000 |
| Working capital and contingency | $1,000 | $2,000 | $2,500 |
| Initial packs producible from raise | ~150 packs | ~280 packs | ~420 packs |
| Estimated Year 1 Revenue (organic only) | $45,000 – $70,000 | $85,000 – $130,000 | $130,000 – $200,000 |
| Estimated break-even timeline | ~10 months | ~8 months | ~6 months |
Revenue projections based on in-house production only, organic word-of-mouth and pilot network conversions, 40% trial-to-repeat rate, and average blended MSRP of $104 per pack. COGS of $29 per pack yields 72% gross margin. Reinvested gross profit funds ongoing batch production from month 2 onward.
$150,000 – $500,000 to fuel organic acquisition and scale
Once operational and generating initial revenue, the growth raise funds an education-led social media strategy across Instagram, TikTok, and Facebook — the primary acquisition channels for the Sovereign ECS target demographic. This is organic influencer and content-led marketing that builds brand authority and community, not paid advertising that disappears when the budget stops. At $150,000 this funds 12 to 18 months of consistent content, influencer partnerships, and community building. At $500,000 it funds a full two-to-three year acquisition engine that drives subscriber numbers to co-packer transition threshold, where COGS drop 20 to 30% and margins expand significantly.
| Growth Scenario | Social Raise | Year 1 Revenue | Year 2 Revenue | Year 3 Revenue | Gross Margin | Break-Even |
|---|---|---|---|---|---|---|
| Organic Bootstrap Only | $0 | $70K – $200K | $200K – $500K | $500K – $1.2M | 71–73% | 6–10 months |
| Partial Growth Raise | $150,000 | $350K – $600K | $900K – $1.5M | $2.0M – $3.2M | 73–76% | ~8 months |
| Full Growth Raise | $500,000 | $800K – $1.2M | $2.0M – $3.0M | $5.0M – $7.0M | 76–80% | ~6 months |
Growth scenarios modelled on 40–50% trial-to-repeat conversion, $80–$120 blended CAC for social-funded scenarios, and co-packer transition at 2,000+ monthly packs enabling 20–30% COGS reduction from Year 2. Full growth scenario targets 3–5x investor return within 36 months. Comparable DTC CBD brand benchmarks: cbdMD 61–66% gross margin; Care/of 65–75%; Hims and Hers 70%+.
Science-Led.
Purpose-Driven.
"I spent 25 years in pharmaceutical and biotech development — working on autoimmune disease and cancer treatments at the highest levels of the industry. In 2017, I had a stroke. That event changed everything."
In the years that followed, Barry turned to the science the pharmaceutical industry had taught him to ignore: the endocannabinoid system, the gut-brain axis, and the natural intelligence of the body when properly supported. What he found was extraordinary — and largely unknown to both patients and practitioners.
Sovereign ECS was born from that research and from conversations with women who had tried everything the conventional system offered and were still searching for something natural, sustainable, and aligned with how their bodies actually work. Barry brings a rare combination of genuine pharmaceutical science depth, five years of ECS-specific formulation research, and the conviction that comes from having experienced the limitations of conventional medicine firsthand.
Two Entry Points.
One Compounding Opportunity.
Sovereign ECS offers two distinct participation opportunities — the operational raise to get the business live, and the growth raise to scale it. Investors may participate in one or both. Both are structured as equity and SAFE agreements designed to align long-term incentives and maximise upside at each stage.
The operational raise is small. The opportunity is not.
$10,000 to $30,000 is a genuinely modest entry to a business with a live formulation, four years of R&D behind it, an active pilot study generating real data, and a market that every major analyst, investor, and media outlet is identifying as one of the defining health investment categories of this decade. Investors who participate in the operational raise access the full upside of the growth stage from a position of maximum equity advantage.
The social media growth raise of $150,000 to $500,000 funds the acquisition engine that takes a live, margin-positive product business to co-packer scale and beyond. The model is capital-efficient by design — high gross margins from launch mean every dollar of the growth raise works harder than in most comparable consumer wellness businesses.